isolated lung metastases that do not respond completely to 6 weeks of chemotherapy. The AREN0533 study was designed to improve event-free survival (EFS) from 75% to 85% for patients with incomplete lung nodule response by adding cyclophosphamide
Search Results
Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez
Wells A. Messersmith
metachronous metastases, primary resection is preferred, with consideration of local therapy or neoadjuvant chemotherapy. The EORTC 40983 trial compared surgery alone with FOLFOX before and after surgery in patients with resectable liver metastases from CRC
Yi-Jen Chen
Over the past 30 years, the incidence of invasive anal carcinoma in the United States has increased at a rate of roughly 2% per year. 1 Most patients present with locoregionally confined disease; distant metastases often involving liver, lung, or
Jilma Patrick and Seema Ahsan Khan
present with de novo stage IV breast cancer. 1 Although systemic therapy is clearly the primary treatment for women with overt metastases, retrospective data published over the past decade have suggested that primary tumor resection (and possibly
Jonathan W. Riess, Seema Nagpal, Joel W. Neal, and Heather A. Wakelee
primary (CK7+, CK20-, TTF1+). The patient's tumor was negative for both KRAS and epidermal growth factor receptor (EGFR)–activating mutations. PET/CT showed the FDG-avid mass in the right upper lobe of the lung, and metastases to the bone, liver, and
David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Thomas J. Dilling, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Steven Schild, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
summarized in this section. Whole-brain RT (WBRT) and stereotactic radiosurgery (SRS) for brain metastases are also discussed in this section. The abbreviations for RT are defined in the algorithm (see Table 1 , page1742). General Principles: Treatment
Paul B. Chapman
. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma . Lancet 1998 ; 351 : 1905 – 1910 . 12 Cascinelli N
Michael A. Gold
metastases—a Gynecologic Oncology Group study . Gynecol Oncol 1990 ; 38 : 425 – 430 . 6. Kim SH Choi BI Han JK . Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients . J Comput Assist Tomogr 1993 ; 17
be enrolled in this multicenter study. Primary Objective: Determine progression-free survival (PFS) [time frame: start of induction, osimertinib up to 22 months] Secondary Objectives: Determine time to appearance of new metastases [time frame: start
) Secondary Objectives: Time to appearance of new metastases, progression of target lesions, and progression of nontarget lesions (time frame: start of induction osimertinib to development of a new lesion, up to 22 months) Adverse events of osimertinib
